Press releases

Interim report Q2 2021

January 1 - June 30 2021

· Net Sales SEK 18 506

· Operation profit SEK -5 836 196

· Profit after financial items SEK -5 782 823

· Earnings per share SEK -0,23

· Numbers of shares 25 293 518

April 1 - June 30 2021

· Net Sales SEK 18 506

· Operation profit SEK -3 623 549

· Profit after financial items SEK -3 570 176

· Earnings per share SEK -0,14

· Numbers of shares 25 293 518

Significant events during the report period (2021-01-01 - 2021-06-30)

· Raytelligence is listed on the Stuttgart Stock Exchange, Germany

· Receives initial order from Careteq, Australia

· Signs agreement with Careteq, Australia

· Pilot order from important municipality, Övertorneå

· Receives call-off order, $ 150,000 from Careteq, Australia

· MDR labeling for Eazense at the Medical Products Agency

· Order from Luleå Municipality

· Warrants TO1 adds approximately SEK 9 million to the company

Significant events after the report period

· Granted a patent by the USPTO

· Raytelligence receives order 23 000 USD from Careteq, Australia

Comments from CEO


Raytelligence now has a lot of pressure on the sales department, which consists of 8 people full time.

We run customer meetings daily, which in most cases results in in-depth study and new meetings with demonstration of the system and proposals for pilot trials.

An important focus we have made is to focus more on partnerships with suppliers who have existing platforms with our key customers to add value in several stages.

Our conscious investment in the municipalities has resulted in a number of orders and pilot installations, including Övertorne, which is one of ten

so-called model municipalities for the digitalization of elderly care.

We see great interest from the municipalities and expect more orders soon.

The volumes in sales will probably be available internationally as the sales cycle is shorter than for municipalities such as has a long decision-making process.Our partner Careteq, Australia has generated a larger order of approximately SEK 1.2 million where deliveries have begun.

Careteq has indicated more major orders intended for the US market.


We continue to add new features in EaZense and customers have chosen our solution when we are compared with competitors both in Sweden and internationally.

We have understood that the product stands well in the competition, especially if you look a little forward in our roadmap.

The existing EaZense is still a medical technology product class 1 and has been updated from MDD to the new requirement MDR.Class 2 certification will, as we previously communicated, apply to our new generation sensor that is under development.We currently see no need to certify an existing product with a higher classification.

However, we now certify EaZense for the important foreign markets, e.g. USA, Canada and Australia. As we now have great pressure in sales and development, I look forward to a continued exciting 2021 together with our customers and investors.

Klas Arvidson

Questions are referred to:

Klas Arvidson, CEO Raytelligence

+46 70 416 98 00

Raytelligence AB (publ)

Klammerdammsgatan 6

302 42 Halmstad


This information is disclosed by Raytelligence AB under the EU Market Abuse Regulation. The information was provided by the above contact person for publication on August 27, 2021 at 08:00 CET.

About Raytelligence AB (publ)

Raytelligence is a Swedish innovation company, based in Halmstad that offers products for monitoring vital parameters, ie breathing, heart rate and movement patterns, based on the company's own 60 GHz radar technology.

Files for download


Press releases and report by E-mail.